170 related articles for article (PubMed ID: 28718418)
1. Novel Insights into Membrane Targeting of B Cell Lymphoma.
de Winde CM; Elfrink S; van Spriel AB
Trends Cancer; 2017 Jun; 3(6):442-453. PubMed ID: 28718418
[TBL] [Abstract][Full Text] [Related]
2. Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies.
Lipowska-Bhalla G; Fagnano E; Illidge TM; Cheadle EJ
Leuk Lymphoma; 2016; 57(6):1269-80. PubMed ID: 27050042
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD20 antibody treatment of non-Hodgkin lymphomas.
Engelhard M
Clin Immunol; 2016 Nov; 172():101-104. PubMed ID: 27531574
[TBL] [Abstract][Full Text] [Related]
4. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.
Maeshima AM; Taniguchi H; Nomoto J; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Matsuno Y
Cancer Sci; 2009 Jan; 100(1):54-61. PubMed ID: 19038008
[TBL] [Abstract][Full Text] [Related]
5. Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab.
Seliem RM; Freeman JK; Steingart RH; Hasserjian RP
Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):18-23. PubMed ID: 16540725
[TBL] [Abstract][Full Text] [Related]
6. Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.
Kubuschok B; Trepel M
Expert Opin Drug Discov; 2017 Jul; 12(7):733-745. PubMed ID: 28494631
[TBL] [Abstract][Full Text] [Related]
7. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
[TBL] [Abstract][Full Text] [Related]
8. The use of ofatumumab in the treatment of B-cell malignancies.
Soe ZN; Allsup D
Future Oncol; 2017 Dec; 13(29):2611-2628. PubMed ID: 28850252
[TBL] [Abstract][Full Text] [Related]
9. Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab.
Ku M; Chong G; Hawkes EA
Blood Rev; 2017 Jan; 31(1):23-35. PubMed ID: 27568879
[TBL] [Abstract][Full Text] [Related]
10. [Rituximab resistance in B-cell lymphoma and its elimination].
Hatake K; Terui Y
Gan To Kagaku Ryoho; 2009 Apr; 36(4):548-51. PubMed ID: 19381025
[TBL] [Abstract][Full Text] [Related]
11. CD37 in B Cell Derived Tumors-More than Just a Docking Point for Monoclonal Antibodies.
Bobrowicz M; Kubacz M; Slusarczyk A; Winiarska M
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333768
[TBL] [Abstract][Full Text] [Related]
12. Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies.
Witkowska M; Smolewski P; Robak T
Expert Opin Investig Drugs; 2018 Feb; 27(2):171-177. PubMed ID: 29323537
[TBL] [Abstract][Full Text] [Related]
13. Targeting B-cell non Hodgkin lymphoma: New and old tricks.
Solimando AG; Ribatti D; Vacca A; Einsele H
Leuk Res; 2016 Mar; 42():93-104. PubMed ID: 26818572
[TBL] [Abstract][Full Text] [Related]
14. Presence of autoimmune disease affects not only risk but also survival in patients with B-cell non-Hodgkin lymphoma.
Kleinstern G; Averbuch M; Abu Seir R; Perlman R; Ben Yehuda D; Paltiel O
Hematol Oncol; 2018 Apr; 36(2):457-462. PubMed ID: 29469175
[TBL] [Abstract][Full Text] [Related]
15. Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma.
Makita S; Hosoba R; Tobinai K
Expert Opin Drug Saf; 2020 Sep; 19(9):1105-1120. PubMed ID: 32715803
[TBL] [Abstract][Full Text] [Related]
16. Targeting an adenosine-mediated "don't eat me signal" augments anti-lymphoma immunity by anti-CD20 monoclonal antibody.
Nakamura K; Casey M; Oey H; Vari F; Stagg J; Gandhi MK; Smyth MJ
Leukemia; 2020 Oct; 34(10):2708-2721. PubMed ID: 32269319
[TBL] [Abstract][Full Text] [Related]
17. Steroid receptor coactivator-3 is a pivotal target of gambogic acid in B-cell Non-Hodgkin lymphoma and an inducer of histone H3 deacetylation.
Zhao Z; Zhang X; Wen L; Yi S; Hu J; Ruan J; Zhao F; Cui G; Fang J; Chen Y
Eur J Pharmacol; 2016 Oct; 789():46-59. PubMed ID: 27370960
[TBL] [Abstract][Full Text] [Related]
18. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.
Shimizu R; Kikuchi J; Wada T; Ozawa K; Kano Y; Furukawa Y
Leukemia; 2010 Oct; 24(10):1760-8. PubMed ID: 20686505
[TBL] [Abstract][Full Text] [Related]
19. Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.
Rufener GA; Press OW; Olsen P; Lee SY; Jensen MC; Gopal AK; Pender B; Budde LE; Rossow JK; Green DJ; Maloney DG; Riddell SR; Till BG
Cancer Immunol Res; 2016 Jun; 4(6):509-19. PubMed ID: 27197068
[TBL] [Abstract][Full Text] [Related]
20. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
